Data Sharing Statement

Shcherbinin. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes. *JAMA Neurol.* Published September 12, 2022. doi:10.1001/jamaneurol.2022.2793

**Data**

**Data available:** Yes

**Data types:** Other (please specify)

**Additional Information:** Lilly provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the US and EU and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, blank or annotated case report forms, will be provided in a secure data sharing environment.

**How to access data:** For details on submitting a request, see the instructions provided at [www.vivli.org](http://www.vivli.org).

**When available:** beginning date: 07-31-2025

**Supporting Documents**

**Document types:** None

**Additional Information**

**Who can access the data:** Investigators whose proposed use of the data has been approved by an independent review committee (“learned intermediary”) identified for this purpose

**Types of analyses:** To achieve aims in the approved proposal

**Mechanisms of data availability:** Proposals should be submitted at [www.vivli.org](http://www.vivli.org) data requestors will need to sign a data sharing agreement. Data for each proposal are available in a controlled access environment.